FDA Approves Talzenna Combination for New Prostate Cancer Use

The U.S. Food and Drug Administration approved talazoparib, marketed as Talzenna, alongside enzalutamide on October 26, 2026, for adults with metastatic prostate cancer that is androgen pathway modulation-naïve or -sensitive. According to the FDA, eligibility requires HRR gene mutations detected with a test authorized by the agency.

For this combination, the FDA recommends a daily oral talazoparib dose of 0.5 mg, with treatment continuing until the disease progresses or toxicity becomes unacceptable. Patients should also receive a GnRH analog unless they have undergone bilateral orchiectomy. The agency directs clinicians to the enzalutamide labeling for that medicine’s dose.

The FDA’s safety information for the combination includes warnings about reduced blood-cell production, myelodysplastic syndrome or acute myeloid leukemia, and embryo-fetal toxicity.

The approval review drew on TALAPRO-3, identified as NCT04821622, according to the FDA. The trial enrolled 599 patients with HRR-mutated metastatic disease in the androgen pathway modulation-naïve or -sensitive setting. Its randomized, double-blind design compared talazoparib against placebo, with enzalutamide given in both groups. Participants were assigned equally between the groups, and androgen deprivation therapy continued for everyone.

According to the FDA, investigator assessments of radiographic progression-free survival favored the talazoparib combination. The median had not been reached among patients receiving talazoparib, while it was 45.8 months among those receiving placebo with enzalutamide. The reported hazard ratio was 0.48, with a 95% confidence interval of 0.36 to 0.65 and a p-value below 0.0001. Assessments used RECIST 1.1 and PCWG3 bone criteria. Overall-survival data remained immature at that analysis, the agency said.

For trial testing, the FDA said researchers prospectively identified HRR mutations by sequencing either tumor tissue or circulating tumor DNA. The trial’s gene set comprised BRCA1, BRCA2, ATM, ATR, PALB2, RAD51C, CDK12, CHEK2, FANCA, MLH1, MRE11A and NBN. That trial testing is distinct from the approval’s requirement that an FDA-authorized test identify qualifying mutations.

The FDA had previously approved the same drug combination on June 20, 2023, for metastatic castration-resistant prostate cancer with HRR mutations. According to the agency, the October 2026 decision adds a separate indication for metastatic disease in the androgen pathway modulation-naïve or -sensitive setting.

* This article is based on publicly available information at the time of writing.